SERVICES

The customer sends us his request through a specication that we will follow to the letter in order to answer
it.
We study the feasibility and carry out the design of innovative medical devices that meet the required
characteristics of efciency, resistance and haemocompatibility included in our client’s specications.

Using simulation and monitoring software, we design and develop innovative medical devices that meet the
client’s requirements.

Our goal is to accompany our customer in his project by our quality work.

3D / 4D numerical simulation, allows to analyse the behaviour of a medical device in an organ in order to study its performance and its impact on blood flow, and thus understand the risks of implantation.

Numerical simulation combined with fluid dynamics, in this case blood flow, provides a useful and efficient vision of the functioning of vital organs. This method, combined with magnetic resonance imaging (MRI), allows us to perform a simulation of the functioning and behaviour of an implantable medical device called CFD: Computational Fluid Dynamic.

Image processing uses artificial intelligence processes to segment desired parts of the anatomy in order to detect abnormalities and the formation or development of medical problems as early as possible.

Mathematical modelling assists in the development of new reliable, adapted, and functional mathematical models to improve the understanding of biomedical engineering issues and model complex dynamic phenomena.

Based on the results obtained during numerical and CFD simulations, we create quality prototypes that meet the requirements of the customer’s specifications.

We can also create a single part of the equipment, certain mechanical components (engine, electronic board), according to the customer’s request.

Our teams are currently working on the design of a high-performance test bench, in collaboration with Virginia Tech to test the prototype and validate the results of simulations and CFD tests.

WE HAVE THE POSSİBİLİTY TO PERFORM İN-VİVO AND İN-VİTRO TESTS ACCORDİNG TO THE CUSTOMER’S REQUEST.

Human Exosome From Stem Cell Product: Human Mesenchymal stem cell from Cord Blood Regenerative medicine therapy based on cell-based therapy is innovatively contributing to the rehabilitation and treatment. The mechanisms of activities of SCs can be explained by exosomes, the content available in body fluids such as blood, serum and cerebrospinal fluid. Exosomes are 30 to 100 nm are membrane-bound extracellular vehicles (EVs). They contain lipids and genetic materials and take part in intercellular communications, via relocating and transferring their contents, from their cells of origin to their target cells. At this time, exosomes have been confirmed to be secreted from various cells including B cells, T cells, dendritic cells, platelets, the Schwann cells, tumor cells, cardio-myocytes, endothelial cells, and stem cells among others. Additionally, exosomes are found in physiological fluids such as urine, plasma, and cerebral fluid and even in organs such as thymus. Secretion of exosome (Exo), trophic factors, and other substances capable of inducing neurogenesis, angiogenesis, contribute to the reduction of inflammation and synaptogenesis, upon administration into the injured or damaged tissue, are significant properties of mesenchymal stem cells (MSCs). On the basis of the ability of micro vesicles (MVs) to mimic stem cell properties, it is speculated that stem cell-derived MVs especially exosomes represent a relevant therapeutic option in regenerative medicine.

Exo-Product Description U/M
Separation Method
Med-CBExo Human Umbilical Cord Blood Mesenchymal Stem Cell Exosomes Frozen/Vial
Ultracentrifuge
Med-BMExo Human Bone Marrow Mesenchymal Stem Cell Exosomes Frozen/Vial Ultracentrifuge
Med-SeExo Human Cord Blood Serum Exosomes Frozen/Vial Ultracentrifuge

ALL cultured cells have been screened negative for Hep-B, Hep-C, HIV-1, HIV-2, SARS COVID19 and Syphilis. All separated exosomes experience includes DLS, SEM, total protein concentration, RNA concentration.
Raposo, H. W. Nijman, W. Stoorvogel et al., “B lymphocytes secrete antigen-presenting vesicles,” The Journal of Experimental Medicine, vol. 183, no. 3, pp. 1161–1172, 1996.View at: Publisher Site| Google Scholar
J. Peters, H. J. Geuze, H. A. van der Donk et al., “Molecules relevant for T cell-target cell interaction are present in cytolytic granules of human T lymphocytes,” European Journal of Immunology, vol. 19, no. 8, pp. 1469–1475, 1989.View at: Publisher Site| Google Scholar
Zitvogel, A. Regnault, A. Lozier et al., “Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes,” Nature Medicine, vol. 4, no. 5, pp. 594–600, 1998.View at: Publisher Site| Google Scholar
F. G. Heijnen, A. E. Schiel, R. Fijnheer, H. J. Geuze, and J. J. Sixma, “Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules,” Blood, vol. 94, no. 11, pp. 3791–3799, 1999.View at: Google Scholar
Fevrier, D. Vilette, F. Archer et al., “Cells release prions in association with exosomes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 26, pp. 9683–9688, 2004.View at: Publisher Site| Google Scholar
Wolfers, A. Lozier, G. Raposo et al., “Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming,” Nature Medicine, vol. 7, no. 3, pp. 297–303, 2001.View at: Publisher Site| Google Scholar
R. Vrijsen, J. P. G. Sluijter, M. W. L. Schuchardt et al., “Cardiomyocyte progenitor cell-derived exosomes stimulate migration of endothelial cells,” Journal of Cellular and Molecular Medicine, vol. 14, no. 5, pp. 1064–1070, 2010.View at: Publisher Site| Google Scholar
Dignat-George and C. M. Boulanger, “The many faces of endothelial microparticles,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 1, pp. 27–33, 2011.View at: Publisher Site| Google Scholar
C. Lai, F. Arslan, M. M. Lee et al., “Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury,” Stem Cell Research, vol. 4, no. 3, pp. 214–222, 2010.View at: Publisher Site| Google Scholar
Pisitkun, R.-F. Shen, and M. A. Knepper, “Identification and proteomic profiling of exosomes in human urine,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 36, pp. 13368–13373, 2004.View at: Publisher Site| Google Scholar
-P. Caby, D. Lankar, C. Vincendeau-Scherrer, G. Raposo, and C. Bonnerot, “Exosomal-like vesicles are present in human blood plasma,” International Immunology, vol. 17, no. 7, pp. 879–887, 2005.View at: Publisher Site| Google Scholar
Bachy, R. Kozyraki, and M. Wassef, “The particles of the embryonic cerebrospinal fluid: how could they influence brain development?” Brain Research Bulletin, vol. 75, no. 2–4, pp. 289–294, 2008.View at: Publisher Site| Google Scholar
Skogberg, J. Gudmundsdottir, S. van der Post et al., “Characterization of human thymic exosomes,” PLoS ONE, vol. 8, no. 7, Article ID e67554, 2013.View at: Publisher Site| Google Scholar

Equipment available in the Lab for flow imaging

6 high speed cameras, including a Photron SA-Z (1 Million frames /s)

A high-speed stereo PIV system (2500 to 25000 Hz, GPU card for post-processing)

Various optics (35 to 200 mm)

2 pulsed lasers for illumination (200 mJ per pulse)

Pressure sensitive paint (PSP) for high-speed wall pressure measurements

User of the Advanced Photon Source (Argonne Synchrotron) for x-ray imaging

OPEN QUESTIONS

Flexibility of the test rig (in terms of pump location, operation mode, measurements)

Test with a simple elastic membrane first, using different materials, before to get a more realistic shape

Installation of the pump into the “ventricle”.

Alternative therapies stemming from the premise the mind, body and spirit function as one and addressing all promotes healing.

MEDRIK DYNAMIC TECHNOLOGY

With our expertise, we help our customers to create a better life.